AN2 Therapeutics, Inc. (ANTX) shareholders
Close on Nov 17, 2026Market cap $159.62MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Michael Kramarz Joint filing with Commodore Capital LP (9.90%), Commodore Capital Master LP (9.90%) and 1 more | 3,697,435 | 9.90% | 13G (passive) | Mar 9, 2026 |
| Vivo Opportunity Fund Holdings, L.P. Joint filing with Vivo Opportunity, LLC (8.00%) | 2,864,346 | 8.00% | 13G (passive) | Mar 10, 2026 |
| Coastlands Capital LP Joint filing with Coastlands Capital Partners LP (9.30%), Coastlands Capital GP LLC (9.30%) and 2 more | 2,815,900 | 9.30% | 13G (passive) | May 28, 2025 |
| Adjuvant Capital Management, L.L.C. Joint filing with Adjuvant Capital GP, L.P. (7.90%), Adjuvant Global Health Technology Fund, L.P. (6.70%) | 2,373,500 | 7.90% | 13G (passive) amendment | Dec 31, 2024 |
| Israel A. Englander Joint filing with Millennium Management LLC (6.30%), Millennium Group Management LLC (6.30%) and 1 more | 2,237,102 | 6.30% | 13G (passive) | Mar 6, 2026 |
| Eric Easom | 2,232,004 | 7.90% | 13G (passive) amendment | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ANTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vivo Capital, LLC | 3,153,640 | 8.36% | $15.26M | – | 1.39% |
| Commodore Capital LP | 2,933,680 | 7.77% | $14.20M | +599,967 | 0.85% |
| Millennium Management LLC | 2,318,692 | 6.14% | $11.22M | +96,190 | 0.00% |
| BlackRock, Inc. | 1,665,494 | 4.41% | $8.06M | +1,346,726 | 0.00% |
| Spruce Street Capital LP | 1,661,073 | 4.40% | $8.04M | – | 1.58% |
| Almitas Capital LLC | 1,469,129 | 3.89% | $7.11M | −10,000 | 1.70% |
| Vanguard Capital Management LLC | 1,238,705 | 3.28% | $6.00M | +227,627 | 0.00% |
| Adage Capital Partners Gp, L.L.C. | 1,000,000 | 2.65% | $4.84M | – | 0.01% |
| Citadel Advisors LLC | 951,997 | 2.52% | $4.61M | +796,758 | 0.00% |
| Boxer Capital Management, LLC | 749,035 | 1.98% | $3.63M | – | 0.27% |
| Geode Capital Management, LLC | 697,806 | 1.85% | $3.38M | +411,259 | 0.00% |
| SummitTX Capital, L.P. | 597,453 | 1.58% | $2.89M | New | 0.07% |
| Balyasny Asset Management L.P. | 556,027 | 1.47% | $2.69M | New | 0.00% |
| Stonepine Capital Management, LLC | 551,692 | 1.46% | $2.67M | −162,153 | 1.51% |
| Ameriprise Financial Inc | 537,064 | 1.42% | $2.60M | −159,117 | 0.00% |
| Sio Capital Management, LLC | 529,933 | 1.40% | $2.56M | −127,267 | 0.42% |
| Ally Bridge Group (NY) LLC | 526,315 | 1.39% | $2.55M | – | 2.25% |
| Prosight Management, LP | 474,638 | 1.26% | $2.30M | −41,116 | 0.40% |
| Woodline Partners LP | 459,805 | 1.22% | $2.23M | −533,866 | 0.01% |
| State Street Corp | 311,602 | 0.83% | $1.51M | +196,400 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 66 | 25M | 65.1% | 28 / 15 | 14 / 14 | 6M | 3M |
| Q1 2026 | 52 | 22M | 58.0% | 25 / 13 | 8 / 9 | 17M | 2M |
| Q4 2025 | 37 | 9M | 23.0% | 5 / 8 | 9 / 3 | 0M | 2M |
| Q3 2025 | 35 | 10M | 25.7% | 2 / 8 | 11 / 3 | 2M | 0M |
| Q2 2025 | 36 | 8M | 22.0% | 8 / 9 | 5 / 9 | 2M | 8M |
| Q1 2025 | 37 | 14M | 38.0% | 5 / 8 | 11 / 5 | 1M | 1M |
| Q4 2024 | 37 | 15M | 38.5% | 12 / 12 | 7 / 6 | 5M | 4M |
| Q3 2024 | 31 | 14M | 35.8% | 9 / 7 | 7 / 22 | 7M | 13M |
| Q2 2024 | 45 | 20M | 51.7% | 6 / 15 | 13 / 14 | 4M | 3M |
| Q1 2024 | 54 | 19M | 49.7% | 18 / 13 | 16 / 15 | 2M | 4M |
| Q4 2023 | 51 | 21M | 54.7% | 16 / 17 | 9 / 2 | 2M | 1M |
| Q3 2023 | 37 | 20M | 52.8% | 14 / 12 | 8 / 8 | 9M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
48 funds held ANTX in Q2 2026, 80% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ANTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 853,017 | 2.26% | $4.13M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 603,086 | 1.60% | $2.92M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 360,114 | 0.95% | $1.74M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 289,229 | 0.77% | $1.55M | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 195,477 | 0.52% | $946.11K | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 122,776 | 0.33% | $531.62K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 88,850 | 0.24% | $430.03K | 0.03% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 64,220 | 0.17% | $343.58K | 0.00% | Jul 31, 2026 |
| Ultra-Small Company Market Fund | 59,000 | 0.16% | $285.56K | 0.19% | Jun 30, 2026 |
| Master Small Cap Index Series | 49,470 | 0.13% | $239.43K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 48,504 | 0.13% | $210.02K | 0.00% | May 31, 2026 |
| Nuveen Small Cap Blend Index Fund | 35,333 | 0.09% | $189.03K | 0.00% | Jul 31, 2026 |
| Dimensional U.S. Small Cap ETF | 35,294 | 0.09% | $188.82K | 0.00% | Jul 31, 2026 |
| Fidelity Series Total Market Index Fund | 34,964 | 0.09% | $151.39K | 0.00% | May 31, 2026 |
| Fidelity Small Cap Value Index Fund | 32,907 | 0.09% | $159.27K | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Eric Easom | Chief Executive Officer, Director | 465,688 | 1.23% | Mar 23, 2026 |
| Joshua M. Eizen | See Remarks | 207,546 | 0.55% | Nov 6, 2026 |
| Cameron C. Trenor III | Chief Medical Officer | 116,667 | 0.31% | Sep 16, 2026 |
| Sarah Joanne Williams | Principal Accounting Officer | 66,311 | 0.18% | Sep 4, 2026 |
| Lucy Day | Chief Financial Officer | 118,363 | 0.31% | Mar 23, 2026 |
| Sanjay Chanda | Chief Development Officer | 118,823 | 0.31% | Mar 23, 2026 |
| Stephen David Prior | Chief Strategy Officer | 59,086 | 0.16% | Jan 7, 2026 |
| Kabeer Aziz | Director | 439,113 | 1.16% | Oct 13, 2026 |
| Gilbert Lynn Marks | Director | 84,156 | 0.22% | Oct 13, 2026 |
| Patricia A. Martin | Director | 19,252 | 0.05% | Oct 13, 2026 |
| Robin Shane Readnour | Director | 566,544 | 1.50% | Sep 11, 2026 |
| Margaret M. FitzPatrick | Director | 10,708 | 0.03% | Sep 2, 2026 |
| Joseph S. Zakrzewski | Director | 145,538 | 0.39% | Aug 14, 2026 |
| Melvin K. Spigelman | Director | – | – | Mar 23, 2026 |
| Stephanie Wong | Director | – | – | Mar 23, 2026 |
| Braden Michael Leonard | 10% owner | 3,017,432 | 8.00% | Jun 16, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Joshua M. Eizen See Remarks | Nov 5, 2026 | Sale | −2,826 | $4.22 | $11.93K | 207,546 |
| Gilbert Lynn Marks Director | Oct 12, 2026 | Award | +2,283 | – | – | 84,156 |
| Patricia A. Martin Director | Oct 12, 2026 | Award | +389 | – | – | 19,252 |
| Kabeer Aziz Director | Oct 12, 2026 | Award | +2,465 | – | – | 61,571 |
| Cameron C. Trenor III Chief Medical Officer | Sep 15, 2026 | Award | +116,667 | – | – | 116,667 |
| Robin Shane Readnour Director | Sep 9, 2026 | Sale(10b5-1 plan) | −523 | $6.02 | $3.15K | 557,467 |
| Robin Shane Readnour Director | Sep 9, 2026 | Sale(10b5-1 plan) | −585 | $6.02 | $3.52K | 624,765 |
| Robin Shane Readnour Director | Sep 8, 2026 | Sale(10b5-1 plan) | −5,294 | $6.02 | $31.87K | 625,350 |
| Robin Shane Readnour Director | Sep 8, 2026 | Sale(10b5-1 plan) | −4,725 | $6.02 | $28.44K | 557,990 |
| Robin Shane Readnour Director | Sep 3, 2026 | Sale(10b5-1 plan) | −3,223 | $6.07 | $19.56K | 630,644 |
| Robin Shane Readnour Director | Sep 3, 2026 | Sale(10b5-1 plan) | −2,877 | $6.07 | $17.46K | 562,715 |
| Sarah Joanne Williams Principal Accounting Officer | Sep 1, 2026 | Sale | −272 | $5.53 | $1.50K | 66,311 |
| Margaret M. FitzPatrick Director | Sep 1, 2026 | Buy | +2,098 | $5.53 | $11.60K | 10,708 |
| Robin Shane Readnour Director | Aug 17, 2026 | Sale(10b5-1 plan) | −18,706 | $6.01 | $112.42K | 633,867 |
| Robin Shane Readnour Director | Aug 17, 2026 | Sale(10b5-1 plan) | −16,696 | $6.01 | $100.34K | 565,592 |
| Joseph S. Zakrzewski Director | Aug 14, 2026 | Gift | −405,880 | – | – | 0 |
| Kabeer Aziz Director | Jul 10, 2026 | Award | +2,852 | – | – | 59,106 |
| Gilbert Lynn Marks Director | Jul 10, 2026 | Award | +2,789 | – | – | 81,873 |
| Patricia A. Martin Director | Jul 10, 2026 | Award | +766 | – | – | 18,863 |
| Joshua M. Eizen See Remarks | Jul 8, 2026 | Sale | −5,945 | $4.17 | $24.79K | 206,554 |
| Sarah Joanne Williams Principal Accounting Officer | May 29, 2026 | Sale | −265 | $4.43 | $1.17K | 66,583 |
| Kabeer Aziz Director | Apr 10, 2026 | Award | +3,775 | – | – | 56,254 |
| Patricia A. Martin Director | Apr 10, 2026 | Award | +1,192 | – | – | 18,097 |
| Gilbert Lynn Marks Director | Apr 10, 2026 | Award | +3,775 | – | – | 79,084 |
| Sarah Joanne Williams Principal Accounting Officer | Mar 3, 2026 | Sale | −327 | $1.06 | $347 | 66,848 |
| Joshua M. Eizen See Remarks | Feb 20, 2026 | Award | +50,000 | – | – | 207,499 |
| Sarah Joanne Williams Principal Accounting Officer | Feb 20, 2026 | Award | +48,375 | – | – | 67,175 |
| Sanjay Chanda Chief Development Officer | Feb 20, 2026 | Award | +38,000 | – | – | 118,823 |
| Lucy Day Chief Financial Officer | Feb 20, 2026 | Award | +38,000 | – | – | 118,363 |
| Eric Easom Chief Executive Officer, Director | Feb 20, 2026 | Award | +112,250 | – | – | 368,630 |
| Patricia A. Martin Director | Jan 12, 2026 | Award | +3,650 | – | – | 16,905 |
| Kabeer Aziz Director | Jan 12, 2026 | Award | +11,560 | – | – | 52,479 |
| Gilbert Lynn Marks Director | Jan 12, 2026 | Award | +11,560 | – | – | 75,309 |
| Sanjay Chanda Chief Development Officer | Jan 6, 2026 | Sale | −5,956 | $1.01 | $6.02K | 75,823 |
| Stephen David Prior Chief Strategy Officer | Jan 6, 2026 | Sale | −2,858 | $1.01 | $2.89K | 59,086 |
| Joshua M. Eizen See Remarks | Jan 6, 2026 | Sale | −6,931 | $1.01 | $7.00K | 152,499 |
| Lucy Day Chief Financial Officer | Jan 6, 2026 | Sale | −5,512 | $1.01 | $5.57K | 75,363 |
| Sanjay Chanda Chief Development Officer | Jan 5, 2026 | Sale | −3,295 | $1.00 | $3.30K | 81,779 |
| Stephen David Prior Chief Strategy Officer | Jan 5, 2026 | Sale | −3,604 | $1.00 | $3.60K | 61,944 |
| Joshua M. Eizen See Remarks | Jan 5, 2026 | Sale | −17,923 | $1.00 | $17.92K | 159,430 |
| Lucy Day Chief Financial Officer | Jan 5, 2026 | Sale | −3,295 | $1.00 | $3.30K | 80,875 |
| Stephen David Prior Chief Strategy Officer | Nov 4, 2025 | Sale | −765 | $1.14 | $872 | 65,548 |
| Joshua M. Eizen See Remarks | Nov 4, 2025 | Sale | −2,819 | $1.14 | $3.21K | 177,353 |
| Patricia A. Martin Director | Oct 10, 2025 | Award | +3,274 | – | – | 13,255 |
| Kabeer Aziz Director | Oct 10, 2025 | Award | +10,367 | – | – | 40,919 |
| Gilbert Lynn Marks Director | Oct 10, 2025 | Award | +10,367 | – | – | 63,749 |
| Patricia A. Martin Director | Jul 10, 2025 | Award | +3,750 | – | – | 9,981 |
| Gilbert Lynn Marks Director | Jul 10, 2025 | Award | +11,875 | – | – | 53,382 |
| Kabeer Aziz Director | Jul 10, 2025 | Award | +11,875 | – | – | 30,552 |
| Eric Easom Chief Executive Officer, Director | Jun 2, 2025 | Buy | +10,000 | $1.07 | $10.70K | 256,380 |
| Braden Michael Leonard 10% owner | May 30, 2025 | Sale | −425,000 | $1.01 | $429.25K | 3,224,432 |
| Braden Michael Leonard 10% owner | May 30, 2025 | Sale | −7,000 | $1.03 | $7.21K | 3,217,432 |
| Braden Michael Leonard 10% owner | May 28, 2025 | Sale | −200,000 | $1.09 | $218.00K | 3,017,432 |
| Braden Michael Leonard 10% owner | May 28, 2025 | Sale | −2,000,000 | $1.16 | $2.32M | 3,749,432 |
| Braden Michael Leonard 10% owner | May 28, 2025 | Sale | −100,000 | $1.16 | $116.00K | 3,649,432 |
| Margaret M. FitzPatrick Director | May 28, 2025 | Buy | +8,610 | $1.18 | $10.16K | 8,610 |
| Kabeer Aziz Director | Apr 10, 2025 | Award | +9,705 | – | – | 18,677 |
| Joseph S. Zakrzewski Director | Apr 10, 2025 | Award | +10,523 | – | – | 145,538 |
| Gilbert Lynn Marks Director | Apr 10, 2025 | Award | +9,705 | – | – | 41,507 |
| Patricia A. Martin Director | Apr 10, 2025 | Award | +3,065 | – | – | 6,231 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of AN2 Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 35,402 shares on Aug 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Robin Shane Readnour Director | Aug 17, 2026 | 1,012,000 | $6.08M | Aug 17, 2026 | Owned Shares |
| Capital Healthcare Fund LP RA Affiliate | Aug 15, 2024 | 1,699,998 | $1.70M | Aug 15, 2024 | private transcation |
| RA Capital Nexus Fund II, L.P. Affiliate | Aug 15, 2024 | 299,999 | $306.00K | Aug 15, 2024 | private transaction |
| Z3 Trust Director | Jan 18, 2024 | 100,000 | $1.91M | Jan 18, 2024 | Private Acquisition from Issuer/Affiliate |
| Adjuvant Global Health Technology Fund, L.P. Shareholder | Jan 16, 2024 | 84,093 | $1.76M | Jan 16, 2024 | Investment fund shares |
| Adjuvant Global Health Technology Fund DE, L.P. Shareholder | Jan 16, 2024 | 15,907 | $332.14K | Jan 16, 2024 | Investment fund shares |
| Mgc Venture Partners Qp 2018 ,lp Officer | Jan 10, 2024 | 11,033 | $237.54K | Jan 10, 2024 | Open Market Purchase |
| Mgc Venture Partners 2018 ,lp Officer | Jan 10, 2024 | 9,443 | $203.31K | Jan 10, 2024 | Open Market Purchase |
| Eric Easom Officer | Jan 2, 2024 | 2,777 | $56.90K | Jan 2, 2024 | Open Market Purchase |
| Kevin Michael Krause Officer | Jan 2, 2024 | 10,000 | $204.90K | Jan 2, 2024 | Exercise of Stock Options |
| Adjuvant Capital GP, L.P. Officer | Nov 14, 2023 | 1,810 | $27.13K | Nov 14, 2023 | Investment fund shares |
| Adjuvant Capital GP, L.P. Officer | Oct 2, 2023 | 5,672 | $91.21K | Oct 2, 2023 | Investment fund shares |
| Adjuvant Capital GP, L.P. Officer | Sep 29, 2023 | 86,398 | $1.38M | Sep 29, 2023 | Investment fund shares |
| Adjuvant Capital GP, L.P. Officer | Aug 23, 2023 | 30,000 | $417.90K | Aug 23, 2023 | Investment fund shares |
See a number that looks wrong?